Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Company Drug

Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...

Company Deals

Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development

Fineline Cube Mar 4, 2025

Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...

Company Drug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

Fineline Cube Mar 4, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...

Company Drug

Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China

Fineline Cube Mar 4, 2025

Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Medical Device

Waters and Kehua’s LC-MS Systems Gain NMPA Approval for IVD Use

Fineline Cube Mar 4, 2025

Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS...

Company Drug

Zai Lab’s Augtyro Receives TFDA Approval for ROS1-Positive NSCLC and NTRK Fusion Solid Tumors

Fineline Cube Mar 4, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received marketing...

Company Deals

Shanghai BioScience Completes RMB 100M Financing Round Led by HUAGAI Capital

Fineline Cube Mar 4, 2025

China-based Shanghai BioScience Co., Ltd., a life sciences service platform, announced the completion of a...

Company Deals Digital

Bayer HealthCare and JD Healthcare Partner on Women’s Health Ecosystem

Fineline Cube Mar 4, 2025

German pharmaceutical giant Bayer HealthCare (ETR: BAYN) has entered into a new partnership with JD...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Medical Device

Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany

Fineline Cube Mar 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its...

Company Deals

Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions

Fineline Cube Mar 4, 2025

Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has...

Company Drug

Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt

Fineline Cube Mar 4, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...

Company Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

Fineline Cube Mar 4, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...

Company Drug

CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors

Fineline Cube Mar 4, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...

Company Deals

AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal

Fineline Cube Mar 3, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...

Company Medical Device

Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA

Fineline Cube Mar 3, 2025

Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...

Posts pagination

1 … 143 144 145 … 606

Recent updates

  • Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
  • Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.